Bio-Rad Laboratories stock
BIONYSEBio-Rad Laboratories, Inc., HealthcareISIN US0905722072
61Score 61 out of 100, Neutral
Price and trend
87 / 100
Price history
+23% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 22% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 63).
The price is 1.1% below its 52-week high. Largest decline in 20 years: 74% (September 2021 to June 2025).
Chart figures for advanced users
- SMA 50$373.74
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$316.28
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)63
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$241.71
- The lowest closing price of the last twelve months.
- Resistance$390.34
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Bio-Rad Laboratories, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $10.38B, is number 21 of 90 companies in its industry on MEQIRI.
- MEQIRI Score 61 out of 100 (Neutral): rank 258 of 714 in Healthcare, median 53.
- The P/E is 10.2 (Medical (Devices) median 29, own median of recent years 8.6).
Show more
- Our model puts fair value at $668.05, with the price 42% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 39.5% over the last 12 months, Medical (Devices) median 3.2%.Profitability 63
- Share buybacksShare count down 8% since 2020.Capital allocation 52
- More cash than debtCash $1.66B, financial debt $1.36B.Stability 85
Weaknesses
- Earnings per share fallingDown 26.3% a year since 2020.Growth 18
- Margin fallingOperating margin 10.5%, average of the prior years 16.6% (to 2024).Profitability 63
Its standout strengths are valuation and technical analysis, while fundamentals and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
What lowers it
- price near its 52-week high
- low growth grade (crashed less often in the backtest)
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $477.18 and expensive above $1,113.42 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $234.44 (cash-flow model) and $1,101.67 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $648.81, at 7.8% it would be $696.89.
Possible value trap: looks cheap, but weak growth.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 1.4% on the twelve months before. Revenue has grown solidly since 2006, at about 4% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 52%, operating 10%, net 29%. Last 12 months: net 39%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 11 Feb 2027in 91 days
- Last reported
- 4 Nov 2026EPS reported $2.65 (expected $2.23)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $9.98+2.4%
- Revenue
- $2.59B0.0%
- Earnings per share
- $10.49−0.1%
- Revenue
- $2.64B−1.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +3.9%Guidance reaffirmed: currency-neutral revenue growth of minus 3% to plus 0.5% and free cash flow of $290 to $340 million, with the second half expected to mirror the first.
“We continue to expect full year currency-neutral revenue growth to be between minus 3% and plus 0.5%. We expect the Life Science segment's currency-neutral growth to be between minus 3% and minus 1% and the Clinical Diagnostics segment's currency-neutral revenue growth to be between minus 3% and plus 1%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $1.25M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Bio-Rad Laboratories
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 61
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Align TechnologyALGN $12.13B71
- Olympus7733.T $11.7B70
- DemantDEMANT.CO $11.62B73
- InsuletPODD $10.41B65
- Globus MedicalGMED $10.12B72
- BrukerBRKR $9.53B53
- GetingeGETI-B.ST $7.6B63
- Shenzhen New Industries Biomedical Engineering300832.SZ $6.9B82
ETFs that hold Bio-Rad Laboratories
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.42% | 0.49% | €318.39M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.73% | 0.40% | €1.49B |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.20% | 0.30% | €5.27B |
Show 5 more
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.08% | 0.30% | €944.34M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.07% | 0.45% | €1.53B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.06% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.04% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.02% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 26 Jun 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.